From Utah to Florida, we shared breakthrough data and connected with leaders at #Eyecelerator, #ARVO2025 & #RetinaWorldCongress.
Thanks to Drs. Bakall, Shah, Haider & Maldonado for representing Ocugen.
đ„ bit.ly/43oF0sG.
#ModifierGeneTherapy #Ocugen
10
82
3,801
19 Dec 2024
Ocugen reports promising interim results for OCU410 clinical trial in geographic atrophy business-news-today.com/ocug⊠#GeographicAtrophy #DryAMD #GeneTherapy #ModifierGeneTherapy #RetinalHealth #Ocugen #VisionRestoration
2
231
Thank you Chardan and Daniil Gataulin, Ph.D. for once again including Ocugen in this informative series. #ModifierGeneTherapy #GA
12
67
3,278
Tomorrow, August 15, Dr. Arun Upadhyay will participate in the panel, âDerisked Late-Stage Candidates for Retinal Disordersâ during H.C. Wainwrightâs 4th Annual Virtual Ophthalmology Conference. #RP #ModifierGeneTherapy #IRD
14
77
3,944
The latest article from Ocugenâs Chief Medical Officer, Dr. Huma Qamar, in Cell & Gene. A special thank you to Neena Haider, Ph.D. for her discovery and the clinical development work of Arun Upadhyay and team. #modifiergenetherapy #courageousinnovation bit.ly/4dUAJl7
24
102
4,169
Ocugen Chairman, CEO and Co-Founder, Dr. Shankar Musunuri, was recently featured in PharmaVoiceâs Biotech Spotlight to discuss the gene-agnostic approach of modifier gene therapy and OCU400âs potential Read more here bitly.ws/3icLi #modifiergenetherapy #blindnessdiseases
24
109
4,976
The latest paper on Ocugen's gene-agnostic approach to treating inherited retinal diseases has been published in Nature. This data further supports the potential for modifier genes to treat various forms of RP. bit.ly/48On6AK @NeenaHaider #IRD #RP #modifiergenetherapy
27
113
8,362
12 Jun 2023
Dr. Neena B. Haider, who developed the modifier gene therapy platform, speaks about inherited retinal diseases and the impact of the platform. Ocugen's focus centers on finding innovative ways to make hard-to-treat blindness diseases a thing of the past! #genetherapy
10
32
2,380
Watch @Ocugen CEO Dr. Shankar Musunuriâs remarks at the Dec. 19 @NasdaqExchange closing bell ceremony. 2022 was highlighted by progress in our two #COVID19 #vaccines and innovative #ModifierGeneTherapy Platform. We are ready and excited to dive into 2023. cdn.jwplayer.com/previews/EnâŠ
40
15
76
21,539
8 Feb 2021
$OCGN has shown that patience pays off and that the good things in life are worth the wait.
#Ocugen #BharatBiotech #COVIDVaccination #Covaxin #ModifierGeneTherapy
2